MedGenome US Appoints Dr. Felix Olale As President & Chief; Jennifer Rose Named As Executive VP & CCO

MedGenome has announced the appointment of two highly respected leaders to spearhead its US operations. Dr. Felix Olale has been named President and Chief Executive Officer (CEO), while Jennifer Rose joins as Executive Vice President and Chief Commercial Officer.

Dr. Olale previously served as Global Co-Lead of Healthcare Investments at LeapFrog Investments. At MedGenome, his leadership will enhance the company’s ability to partner with academic institutions, biopharma, and biotech firms, providing them with innovative multiomic and genomic tools essential for groundbreaking scientific research and drug development.

MedGenome’s offerings include an extensive suite of multiomic services that span genomics, epigenomics, transcriptomics, and proteomics. Their team of expert scientists and bioinformaticians collaborates closely with clients to address complex challenges in fields such as oncology, rare diseases, and genetic disorders.

Dr. Olale’s new role as CEO follows his tenure as Chairman of MedGenome’s Board of Directors, where he was instrumental in shaping strategic priorities. He takes on this position as Dr. Amit Kakar, Managing Partner and Head of Novo Holdings Asia, assumes the role of Chairman.